Building Wealth Cancer is the second-leading cause of death in the U.S.
I'd bet most everyone reading this has known someone who died of cancer.
Despite the staggering death rate, and the millions of dollars spent on cancer research, we haven't made a lot of strides in stopping cancer deaths.
The death rates for cancers like breast, prostate, colorectal, liver, and pancreatic haven't changed significantly since the 1930s. By comparison, stroke and heart-disease death rates fell 74% and 64%, respectively, between 1950 and 2006. And according to a study in Circulation, these rates have continued to fall, though at a slower pace, through 2013.
That's in large part because the basic weapons in our arsenal to fight cancer – surgery, chemotherapy, and radiation – haven't changed in decades.
Until now...
Tonight, at 8 p.m. Eastern time, my colleague Dave Lashmet and I will discuss the new cancer breakthrough that could soon be a staple in every U.S. hospital.
Right now, you can't find this story anywhere in the mainstream press...
Not in the Wall Street Journal or the Financial Times. It's not on CNBC. It's not in Wired. It's not even in the New England Journal of Medicine.
We're breaking the news to the public TONIGHT...
This is a company very few American investors have ever heard of, with three major U.S. Food and Drug Administration approved products, and over $1 billion of sales.
But it's this company's latest discovery that Dave predicts will revolutionize cancer medicine, and send the stock soaring. This breakthrough is so powerful and unique, Dave says it's going to dominate its market.
In short, one company owns the patents to the world's most powerful and proven new cancer breakthrough.
And as you know, once you have a patent... you essentially have a legal monopoly... which often amounts to a fortune in the world of biotech.
For example, all blockbuster drugs are pretty much monopolies...
- Like Amgen's (AMGN) Epogen, the first biotech drug, is protected by one patent. The stock is up more than 16,000% since approval.
- Roche's (ROG.VX) Herceptin is now a $6.5 billion drug, protected by one patent.
- And Pfizer's (PFE) Lipitor, protected by one patent, holds the record for being one of the highest grossing drugs of all time.
Bottom line: patents equal huge potential gains in the biotech world.
And tonight, we'll tell you about the company that owns all the patents for what could soon be the gold standard of cancer treatment in America.
This will soon be front-page news.
We'll tell you more during our live event tonight at 8 p.m. Eastern time.
And even if you choose to ignore the investment opportunity... this breakthrough is a lot more important than just money.
You see – for years, we've discussed cancer in investment terms only.
But as you'll see, this story is a lot bigger than that.
Just imagine losing a loved one who could have been helped by a treatment your doctor didn't know about yet. What we'll tell you about tonight will give you the best shot at making sure that NEVER happens.
This is your last chance to reserve your seat for tonight.
Here's to our health, wealth, and a great retirement,
Dr. David Eifrig and the Retirement Millionaire Daily Research Team
Baltimore, Maryland
November 15, 2017
P.S. Just for showing up tonight, you'll receive a free copy of my book, The Living Cure. Click here to reserve your spot.